University of Notre Dame Australia   Report issue

Academic/Hospital Phase 3 Phase 4
Founded: Fremantle Australia (1989)

Organization Overview

First Clinical Trial
2015
NCT03553277
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

University of Notre Dame | University of Notre Dame Australia

Active Ingredients

Drugs in Phase 4 Trials (2)

artemether (1 trial)

lumefantrine (Coartem) (1 trial)

Drugs in Phase 3 Trials (2)

acetylcysteine (mucomyst) (1 trial)

vitamin c (1 trial)

Drugs in Other Trials (1)

transfluthrin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Headache (Phase 3)

Malaria (Phase 4)

Migraine Disorders (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5